Torsdag 2 April | 02:43:42 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-08-20 07:30 Kvartalsrapport 2026-Q2
2026-04-07 N/A X-dag ordinarie utdelning GUBRA 0.00 DKK
2026-03-26 - Årsstämma
2026-02-27 - Bokslutskommuniké 2025
2025-08-21 - Kvartalsrapport 2025-Q2
2025-06-30 - X-dag bonusutdelning GUBRA 61.2
2025-06-27 - Extra Bolagsstämma 2025
2025-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2025-04-03 - Årsstämma
2025-02-28 - Bokslutskommuniké 2024
2024-08-23 - Kvartalsrapport 2024-Q2
2024-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2024-04-03 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-01 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-03-26 13:09:00

On Thursday, 26 March 2026 at 10:00 am (CET), the annual general meeting of Gubra A/S (the "Company") was held at the Company's registered address Hørsholm Kongevej 11B, DK-2970 Hørsholm, with the following agenda:
 

1. The board of directors’ report on the Company’s activities during the past financial year
2. Presentation of the audited annual report for adoption
3. Resolution on the appropriation of profit or payment of loss in accordance with the adopted annual report
4. Presentation of and advisory vote on the remuneration report
5. Proposal from the board of directors to approve the company's remuneration policy
6. Approval of remuneration of the board of directors for the current financial year
7. Election of members to the board of directors
8. Election of auditor
9. Authorisation to acquire treasury shares
10. Proposal from the board of directors to renew and increase the existing authorisation to issue warrants
11. Proposal from the board of directors to remove articles 6.5 and 6.5.1 of the Company's articles of association
12. Any proposals from the shareholders
13. Authorisation to the chairman of the general meeting
14. Any other business

 
Re item 1
The general meeting acknowledged the report of the board of directors on the Company’s activities during the past financial year.
 
Re item 2
The general meeting adopted the 2025 annual report.
 
Re item 3
The general meeting approved the proposal to carry forward the result of the year as recorded in the adopted annual report to the following financial year.
 
Re item 4
The general meeting approved the Company's remuneration report by advisory vote.
 
Re item 5
The general meeting approved the Company's remuneration policy.
 
Re item 6
The general meeting approved the proposed remuneration of the board of directors for the current financial year. The remuneration level is slightly increased compared to 2025 as presented under agenda item 6 in the notice convening the annual general meeting.
 
Re item 7
The general meeting approved the re-election of Monika Lessl, Alexander Thomas Martensen-Larsen, Niels Vrang, Jacob Jelsing, Astrid Haug, Claudia Mitchell and Arndt Justus Georg Schottelius.
 
The board of directors has re-elected Monika Lessl as chair of the board of directors and Alexander Thomas Martensen-Larsen as deputy chair of the board of directors.
 
Re item 8
The general meeting approved the re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC) as the Company's auditor for financial purposes.
 
Re item 9
No proposal had been made under this agenda item, as the board of directors in connection with the IPO was authorised in the period until 14 March 2028 to approve the acquisition of treasury shares, on one or more occasions, with a total nominal value of up to 10% of the share capital of the Company. The consideration may not deviate more than 10% from the official price quoted on Nasdaq Copenhagen A/S at the time of the acquisition.
 
Re item 10
The general meeting approved to renew and increase the existing authorisation to issue warrants as presented under agenda item 10 in the notice convening the annual general meeting.
 
Re item 11
The general meeting approved to remove articles 6.5 and 6.5.1 of the Company's articles of association as presented under agenda item 11 in the notice convening the annual general meeting.  
 
Re item 12
No proposals from shareholders had been submitted.
 
Re item 13
The general meeting authorised the chairman of the general meeting to register the resolutions with the Danish Business Authority.